ArriVent BioPharma (AVBP) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
28 Apr, 2026Executive summary
Annual meeting scheduled for June 18, 2026, with voting open until June 17, 2026 at 11:59 PM ET.
Shareholders can access proxy materials online or request paper/email copies by June 4, 2026.
Meeting will be held virtually, allowing remote participation and voting.
Voting matters and shareholder proposals
Election of three directors: James Healy, John Hohneker, and Stuart Lutzker, all recommended by the board.
Ratification of PricewaterhouseCoopers LLP as independent auditor for fiscal year ending December 31, 2026.
Provision for other business to be addressed as may properly come before the meeting.
Audit committee and external auditor matters
Proposal to ratify PricewaterhouseCoopers LLP as the independent registered public accounting firm for the upcoming fiscal year.
Latest events from ArriVent BioPharma
- Firmonertinib and novel ADCs show strong clinical progress, with major milestones ahead in 2026.AVBP
Corporate presentation - Q2 2026 net loss widened to $49.9M as pivotal NSCLC trials advance, with $373.1M in cash.AVBP
Q2 2026 - Directors were elected through 2029 and the auditor's appointment was ratified with strong support.AVBP
AGM 2026 - Firmonertinib and next-gen ADCs drive a late-stage oncology pipeline with major 2026 milestones.AVBP
Corporate presentation - Q1 2026 net loss narrowed to $43.3M; strong cash position and pipeline progress continue.AVBP
Q1 2026 - Virtual meeting to elect directors, ratify auditor, and review compensation and governance.AVBP
Proxy filing - Pivotal NSCLC trials advanced, ADC pipeline expanded, and cash runway extends into 3Q 2027.AVBP
Q4 2025 - Virtual annual meeting to elect directors and ratify auditor, with updated governance and compensation.AVBP
Proxy Filing - Firmonertinib showed 68.2% ORR and 16.0 months mPFS in 1L EGFR PACC mutant NSCLC.AVBP
Study Update